QuantumPharm (2228.HK) and Fangda Carbon (600516.SS) launch an AI-driven manufacturing system designed to improve production efficiency and reduce costs in graphite electrode fabrication.
XtalPi's AI model has successfully transitioned from development to operational status within Fangda Carbon's production environment. By passing comprehensive acceptance testing, the company has validated its industrial AI capabilities, specifically in the domain of graphite electrode manufacturing optimization.
The model forecasts performance and screens formulations before physical trials to optimize costs.
Fangda Carbon has officially deployed a jointly developed AI system that has met its internal cost optimization benchmarks. This operational milestone suggests a shift toward data-driven manufacturing, which is expected to enhance production efficiency and reduce trial-related expenses.
It enables rapid screening of formulations and performance forecasting, reducing the need for physical trials.
QuantumPharm Inc. (XtalPi) and Fangda Carbon have successfully integrated a proprietary AI model into the latter's graphite electrode manufacturing workflow. The system, which passed comprehensive acceptance testing, optimizes production costs by forecasting performance and screening formulations prior to physical trials.
The model optimizes production by forecasting performance and screening material formulations before physical trials, which reduces costs and increases manufacturing efficiency.